Lv41
640 积分 2025-02-27 加入
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
9小时前
已完结
tezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): phase 3 trial
9小时前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
9小时前
已完结
Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription
22天前
已完结
肝内胆管癌动物模型和类器官的研究进展
22天前
已完结
Tumour fatty acid metabolism in the context of therapy resistance and obesity
1个月前
已完结
EPLINα controls integrin recycling from Rab21 endosomes to drive breast cancer cell migration
1个月前
已关闭
A. Flow cytometry enables rapid evaluation of novel, new and niche antimicrobial agents
1个月前
已完结
Macrophages-aPKCɩ-CCL5 Feedback Loop Modulates the Progression and Chemoresistance in Cholangiocarcinoma
2个月前
已完结
TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
3个月前
已完结
皖公网安备34019202002308
